Merck & Co expands the portfolio of anticarcinogenic preparations at the expense of the transaction from Seattle Genetics Inc

Yevropeyskaya commission approved the preparation ADTSETRIS® (brentuksimab vedotin) for application for adult patients earlier not receiving treatment...

IPO недели: швейцарский разработчик лекарств от рака крови выйдет на NYSE

Market of United States of America. Indexes grow before squall of reports

The recommendation about stocks Seattle Genetics Inc] is raise

The forecast on stocks Seattle Genetics Inc] is raise

The latest preparation from leukemia was deadly

Stock market United States of America opened in the positive territory